SD

VISION for a world free from infectious and neglected diseases Annual Report 2015 Our Mission is to reduce needless human suffering from -preventable and neglected tropical diseases (NTDs) by developing new , advocating increased use of existing vaccines and promoting expanded access to affordable medical treatments. Table of Contents

2 Leadership 3 Letter from the Chairman and the CEO 4 Vaccine Development 10 Vaccine Advocacy and Education 18 Global Network 24 Sabin Foundation Europe 26 Awards and Recognition 27 Finances

1 Leadership

Axel Hoos, M.D., Ph.D. Chairman, Sabin Vaccine Institute;

Senior Vice President, Oncology R&D, GlaxoSmithKline Pharmaceuticals

Amy Finan Chief Executive Officer

Peter J. Hotez, M.D., Ph.D. President, Sabin Vaccine Institute; Director, Sabin PDP, Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine

Jon Andrus, M.D. Executive Vice President, Sabin Vaccine Institute; Director, Vaccine Advocacy and Education

Brian Davis, C.P.A. Chief Operating Officer

2 Charting our Future

Letter from the Chairman and the CEO

It is an honor for us to lead and serve the Sabin Vaccine Sabin’s collaboration with the governments of Nepal and Institute as Chairman and CEO. For 22 years, this Uganda helped these countries take strong steps toward organization has fought tirelessly to improve health country ownership through legislation, as both countries for marginalized communities around the world by passed laws to establish and protect domestic funding strengthening immunization programs, improving access for immunization. The International Association of to basic medical treatments and advancing novel vaccines Immunization Managers held its first global conference, to prevent infectious and neglected tropical diseases attended by immunization managers from more than 70 (NTDs). countries. Sabin completed a dengue surveillance project in 2015 with the Pan American Health Organization and Sabin continues to embody the indefatigable drive for is providing the information countries need to make progress of our namesake, Dr. Albert B. Sabin, inventor informed decisions regarding new dengue vaccines. of the oral and lifelong crusader against poverty and preventable disease. Even as we celebrate Sabin also advanced our vaccine candidates, including the near success of the decades-long effort to eradicate initiating clinical trials for a vaccine candidate to prevent polio, we face threats both new and familiar – Zika, the , the second most common parasitic resurgence of dengue and measles, which continues disease after malaria and the deadliest of the most to be one of the leading causes of death among young common NTDs. 2015 saw significant global policy wins, children. with commitments from the G7 and BRICS countries to invest in NTDs. Sabin’s mission is as important as ever. Despite tremendous progress, 20 percent of children miss out on We thank Ambassador Michael Marine for his leadership routine vaccines, more than a billion people suffer from as CEO over the past six years and look forward to his NTDs, and we have learned just how vulnerable we are to ongoing guidance as a member of Sabin’s board of unforeseen disease outbreaks. To meet these challenges trustees. We are excited to define Sabin’s next chapter, will require a concerted effort to develop new vaccines, guided by the principles of equity, sustainability and build capacity to introduce vaccines, encourage country country ownership. Through the passion of our dedicated ownership of immunization programs, and improve team, the board and our partners, Sabin will continue to not only immunization rates but also access to data for lead the way toward a healthier future informed decision making.

Through education and training, advocacy and vaccine development, Sabin advances solutions to some of the world’s most prevalent health problems. Sabin acts as a catalyst, a champion and a coalescing force to focus the use of immunization science in the service of people everywhere. In 2015, years of effort by Sabin bore striking Morton P. Hyman Michael W. Marine, Peter J. Hotez, results. Chairman Ambassador (Ret.) M.D., Ph.D. CEO President

3 VACCINE DEVELOPMENT Developing safe, low-cost vaccines

4 Vaccine Development

NTDs affect an estimated one-sixth of the world’s population, but these diseases do not receive nearly their share of investments in research and development. The Sabin PDP translates scientific research into life-saving products to prevent NTDs and emerging viral .

For more than 15 years, the Sabin Vaccine Institute The Sabin PDP is conducting vaccine research Product Development Partnership (Sabin PDP) has and development for hookworm, schistosomiasis, pioneered the development and testing of low-cost leishmaniasis, , trichuriasis (whipworm), vaccines to prevent and treat NTDs and emerging viral ascariasis (roundworm), (river blindness), infections. Because NTDs overwhelmingly affect people West Nile virus, severe acute respiratory syndrome living in poverty, this research is typically overlooked by (SARS) and Middle East respiratory syndrome (MERS). As pharmaceutical companies. vaccine candidates for hookworm and schistosomiasis advance through clinical trials, the Sabin PDP is In partnership with academic institutions, non-profit evaluating opportunities to partner with developing organizations and governmental agencies around the country vaccine manufacturers for the eventual scale up globe, the Sabin PDP has built a platform to develop and of production for NTD vaccines and build the case for test vaccine candidates and advance them through early investment in these products. product and clinical development.

5 Vaccine Development

Building Global Research Expertise

Sabin is helping low- and middle- income countries establish vaccine development capacity to respond to the burden of NTDs and prevent future disease outbreaks.

Peter Hotez, MD, PhD, is president of Less than a year after the Ebola crisis, the spread Sabin and director of the Sabin PDP. of Zika once again exposed the critical need for increased vaccine research and development capacity around the world.

To prevent and control future outbreaks, Sabin is committed to advancing global capacity for vaccine WHAT'S NEXT research and development. In his role as U.S. Science Envoy, Sabin’s President, Dr. , is The Sabin PDP will train counterparts bringing attention to the growing threat of disease from King Saud University in vaccine development at its headquarters at in the Middle East and North Africa due to conflict the Texas Medical Center in Houston, and post-conflict conditions. To build capacity for Texas, in partnership with Texas vaccine research in the region, Sabin is partnering Children’s Hospital and Baylor with King Saud University in Saudi Arabia, leveraging College of Medicine. a training model established with the University of Malaya in Malaysia.

6 Vaccine Development

Preventing Snail Fever

Schistosomiasis is a parasitic disease carried by freshwater snails, which infects people in as many as 78 countries, with the vast majority of the burden in Africa.

In 2015, the Sabin PDP began the first clinical trial in humans for a vaccine candidate to prevent WHAT'S NEXT schistosomiasis – also known as snail fever – which The Sabin PDP plans to test the vaccine infects more than 250 million people worldwide and in schistosomiasis-endemic areas of kills an estimated 280,000 people each year in Africa South America and Africa. alone. Schistosomiasis is the second most common parasitic disease after malaria and the deadliest of the most common NTDs.

The Sabin PDP is developing a business case for the that will address the global need for the vaccine; the process of research, development and commercialization; financial modeling; and a funding strategy.

7 Vaccine Development

Protecting Against Hookworm

Hookworm is both a symptom and a source of poverty. Infecting nearly half a billion people worldwide, it is a major cause of malnutrition and anemia in pregnant women and children.

Dr. Maria Elena Bottazzi is Deputy In 2015, the Sabin PDP completed clinical trials in Director of the Sabin PDP, based in Washington, D.C. and Brazil for its most advanced the Texas Medical Center in Houston, product, the Human . These Texas, at Texas Children’s Hospital trials evaluated safety and immune response for two and Baylor College of Medicine. promising vaccine candidates to prevent human , which infects one-quarter to one-third of all pregnant women in Africa and can lead to serious health risks during pregnancy and childbirth.

Additional clinical trials are ongoing in the United WHAT'S NEXT States, as well as in hookworm-endemic areas in The Human Hookworm Vaccine Gabon and Brazil. The successful completion of will be evaluated for its safety and these trials would be a significant step toward the immune response in healthy adults first vaccine specifically targeting iron-deficiency and children in Brazil and Gabon. anemia in low- and middle-income countries, where hookworm infection is widespread.

8 Vaccine Development

Disease Prevalence

SCHISTOSOMIASIS HUMAN HOOKWORM

SOIL-TRANSMITTED HELMINTHS CHAGAS DISEASE

CUTANEOUS LEISHMANIASIS ONCHOCERCIASIS

WEST NILE DISEASE SARS AND MERS

9 VACCINE ADVOCACY AND EDUCATION Expanding access to vaccines

10 Vaccine Advocacy and Education

Successful immunization programs require much more than just vaccines. Sabin works to improve the delivery, technical capacity and financing of national immunization programs around the world.

One in five children does not receive basic Sabin brings together national governments, policy immunizations. Guided by the principles of equity, makers, immunization specialists, researchers and sustainability and country ownership, Sabin’s Vaccine advocates to strengthen immunization programs and Advocacy and Education programs seek to extend the achieve the 2020 goals set by the Global Vaccine Action benefit of immunization to everyone. Plan.

New vaccines can take years to reach low-income countries. Sabin works to accelerate access to life- saving vaccines for those most at risk, advocating for effective vaccines and better data for decision making, conducting research, training immunization professionals and working with countries to expand and protect their immunization budgets.

11 Vaccine Advocacy and Education

Fighting Typhoid Together

The Coalition against Typhoid (CaT) works to prevent typhoid through research, education and advocacy.

Typhoid fever, an infection spread through 200,000 contaminated food and water, kills more than the number of people that die every 200,000 people every year, most of whom are year from typhoid fever. children. CaT engages stakeholders to support solutions for typhoid and related diseases, including vaccines and clean water. In 2015, CaT convened more than 200 researchers, policy makers and 27 representatives from international organizations countries have reported drug- from 43 countries at its ninth international resistant strains of typhoid fever. conference in Indonesia. The conference highlighted the spread of drug-resistant typhoid across Africa and Asia, underscoring the urgent need to introduce new vaccines to protect young children and other at-risk populations. WHAT'S NEXT CaT launched a new strategy to increase advocacy CaT will implement new activities in activities and expand coalition membership to 2016, such as convening leaders to additional health sectors including water, sanitation share best practices and providing advocacy training and resources to and hygiene. A leader in research, CaT initiated the typhoid leaders in Africa and Asia. second phase of its Surveillance for Enteric Fever in Asia Project (SEAP) in 2015. SEAP is one of the CaT will continue working on typhoid few studies to characterize the complications and surveillance in Bangladesh, India, severity of typhoid in addition to disease burden, Nepal and Pakistan to determine the which will assist countries in making decisions burden of disease in these countries. regarding vaccine implementation.

12 Vaccine Advocacy and Education

Fostering Country Ownership of Immunization Programs

The Sustainable Immunization Financing (SIF) program works alongside government officials in Europe, Africa and Asia to achieve country ownership of immunization through domestic immunization financing.

As low- and middle-income countries grow Photo: Hon. A.B.D. Sesay, parliamentarian from Sierra their economies, they become ineligible for the Leone, speaks at 2015 peer review workshop. donor funding that had supported many of their Following a 2015 workshop, three countries immunization programs. These countries are now secured substantial budget increases for immunization. and Africa. developing long-term, domestic financing solutions Approved Government Routine to support immunization. SIF works with health and Immunization Budgets 2015-2016 finance officials in these countries as they navigate this transition.

SIF is supporting 16 of its partner countries in legislative projects. In 2015, SIF played a vital role in the passage of immunization legislation in Uganda and Nepal, providing briefings on novel financing approaches and bringing parliamentarians together with ministry officials to draft and advance legislation.

SIF provides country officials with tools to analyze budgets and advocate for increased government immunization spending. During a 2015 SIF workshop, representatives from Mali, Senegal and Cameroon prepared evidence-based investment cases and practiced advocating for increased immunization budgets. Within six months, all three Sources: Ministry of Health Reports to Sabin SIF field officers. countries secured budget increases.

WHAT'S NEXT In 2016, SIF is hosting four regional workshops and its third international colloquium, which will bring together counterparts from each of SIF’s partner countries to exchange ideas and share news regarding their progress on immunization financing.

13 Vaccine Advocacy and Education

Improving Immunization Programs through Management Training

The International Association of Immunization Managers (IAIM) is the only international professional association dedicated to immunization managers, offering opportunities to connect, share knowledge and strengthen management and leadership skills in order to advance immunization program performance.

IAIM helps members from more than 100 countries WHAT'S NEXT prepare for the future by investing in management IAIM will host a regional meeting skills to advance their immunization programs. in China for its members from Asia Better performing programs will be required not only and the Pacific in 2016. A key theme to extend the benefits of life-saving vaccines to the will be the elimination of measles 20 percent of children who do not currently receive and rubella as an opportunity to them, but also to introduce a new generation of strengthen health systems and promote global health security. vaccines targeting older children and adults.

Photo: Theresia Sandra Diah Ratih, IAIM member from Indonesia, at the 2015 global conference. 2015 was a year of firsts for IAIM, which held its first global conference, attended by members from more than 70 countries, and empowered IAIM members to take ownership of the association, electing their own governing council for the first time. IAIM launched its Training Scholarship Program in 2015, facilitating journeys across the country or around the world for its members to participate in valuable training programs. IAIM also grew its membership in 2015, particularly in Francophone countries.

14 Vaccine Advocacy and Education

Training Scholarships & Peer-to-Peer Exchanges

IAIM members from 19 countries have participated in Training Scholarships and Peer-to-Peer Exchanges since IAIM's launch in 2013.

Peer-to-Peer Training Scholarships

15 Vaccine Advocacy and Education

Special Projects

Sabin helps endemic countries make informed decisions about introducing new and underutilized vaccines.

LEADERSHIP IN DENGUE PREVENTION Sabin and the Pan American Health Organization (PAHO) completed the Dengue Surveillance Project in 2015, which created a disease surveillance model to help countries in Latin America and the Caribbean make decisions regarding new dengue vaccines. Sabin also hosted the First Regional Dengue Symposium in Brazil, where attendees from 16 countries learned about new research that will inform decisions on dengue vaccine introduction in endemic countries.

CIRO DE QUADROS VACCINOLOGY COURSE Since 2011, Sabin’s vaccinology course has trained more than 175 delegates from Latin America and Caribbean on the fundamentals of epidemiology and immunology, current immunization recommendations, funding mechanisms, effective communication, and challenges facing immunization programs. At this year’s course, more than 40 participants were introduced to an entirely new curriculum, which will be the basis of a bilingual vaccinology textbook.

16 Vaccine Advocacy and Education

PROVAC INTERNATIONAL WORKING GROUP Sabin partners with PAHO on the ProVac Initiative, which works with developing countries to strengthen their ability to make data-driven decisions on vaccine introduction. In 2015, Sabin designed a strategy to implement the ProVac methodology in countries engaged in Sabin’s Sustainable Immunization Financing Program, to provide guidance as these countries carry out their own studies to assess the cost-effectiveness of introducing new vaccines.

CONVENING THOUGHT LEADERS Over the past five years, Sabin has brought together more than 2,000 attendees from nearly 100 countries at more than 20 meetings. In 2015 alone, Sabin convened attendees from more than 25 countries at conferences and meetings concerning the status of the global measles control program, research on rubella, surveillance strategies for meningococcal disease, and more.

WHAT'S NEXT Sabin looks to expand its work into monitoring and evaluation while continuing to develop evidence to ensure vaccines and immunization strategies are saving more lives more quickly.

17 GLOBAL NETWORK Putting the spotlight on neglected tropical diseases

18 Global Network

Neglected tropical diseases (NTDs) impact more than a billion people around the world, yet they receive scant political or public attention, and programs to prevent and control these devastating diseases are chronically underfunded.

NTDs are inextricably linked to poverty. They impact We also work with in-country partners to improve the vulnerable populations, causing disfigurement and success of NTD prevention and treatment programs. disability, and leading to physical and developmental For example, the Global Network coordinated with the delays in children. Many of these diseases can be treated Indian government and partners in 2015 to arrange a with medicine donated by pharmaceutical companies; site visit for Indian journalists to learn about lymphatic it’s just a matter of getting these drugs to the people filariasis (also known as elephantiasis). The journalists who need them. In fact, it costs less than 50 cents per interviewed people living with lymphatic filariasis year to protect one person against the most common to understand the challenges they face in the rural, NTDs. remote villages where they live. This resulted in more than a dozen unique media pieces in four languages, Sounds simple, right? But more than 800 million children encouraging participation in nationwide drug distribution are still at risk of contracting one or more NTD. Through programs. the work of the Global Network, Sabin has been a leading advocacy organization for NTDs, dedicated to raising the awareness, political will and funding required to eliminate these diseases as a public health threat to the world’s poorest communities. Sabin works to achieve this by cultivating advocates at every level – from college students to parliamentarians – to get NTDs onto national, regional and international development agendas.

19 Global Network

NTDs on the Global Stage

The Global Network contributed to significant global policy victories in 2015, unifying partners to secure a place for NTDs on the global development agenda.

Photo: NTD Special Envoy Dr. Mirta Roses met Leading up to the 2015 G7 Summit, the Global with Professor Keizo Takemi, member of Japan's legislature, to urge Japan to prioritize NTDs on the Network facilitated the first-ever NTD community G7 agenda. letter to G7 Heads of State. This letter, which brought together more than 100 signatories, was a key component of Sabin’s strategy to ensure a “With relatively little material effort, robust, concrete outcome for NTDs. Prior to the the suffering of hundreds of millions Summit, the Global Network and the German NTD of people could be combatted.” Network also raised awareness within Germany – German Chancellor Angela Merkel, of the pressing need for greater access to NTD on the subject of NTDs, World Health treatments and the resource gaps for neglected Assembly Opening Address diseases. These efforts came to fruition at the 2015 Summit, where member countries renewed commitments to fight NTDs, pledging to invest in prevention, treatment and research.

Other countries play a vital role in NTD control and elimination. In 2015, the Global Network urged officials from BRICS countries – Brazil, Russia, India, China and South Africa – to renew their commitments to combatting NTDs. BRICS leaders WHAT'S NEXT incorporated the fight against NTDs into two Sabin is working to persuade global separate declarations in 2015, demonstrating their policy makers to translate their commitment to relieving suffering for those in need. commitments to fight NTDs into concrete initiatives, advancing efforts Following a successful two-year effort to secure to achieve NTD-related targets in the a place for NTDs in the Sustainable Development SDGs and improving health outcomes for people around the world. Goals (SDGs), the Global Network fought for the inclusion of an indicator to measure progress against NTDs. After months of advocacy, the indicator received a green light in late 2015.

20 Global Network

Mobilizing the Next Generation of Advocates

Through END7, the Global Network is inspiring and educating a new generation of global health professionals to combat NTDs.

END7, an international advocacy campaign led by Sabin, engages the public to raise awareness of NTDs and urge world leaders to prioritize these diseases of poverty. In 2015, thousands of people around the world joined END7’s advocacy campaign to the UN, asking their ambassadors to support an NTD indicator in the SDGs. Thousands more Americans wrote to their Members of Congress and President to ask that they protect NTD funding.

In 2015, END7’s student outreach program grew to include young leaders at more than 50 universities in 15 countries. Students published op-eds and research papers, led creative advocacy campaigns, and engaged in education and fundraising on university campuses from Scotland to Sierra Leone. To date, END7 students have raised more than $100,000 for NTD treatment programs.

END7 held its first Student Advocacy Day in 2015, bringing 20 students to Washington, D.C., for nearly WHAT'S NEXT two dozen meetings with Members of Congress and their staff, urging them to maintain and grow END7 will continue to advocate for USAID funding for NTDs. This event grew in 2016, increased U.S. support of NTD treatment with 40 students from 15 universities participating programs. This year, the campaign is approaching $1 million in donations to in 39 meetings with key congressional offices. The help deliver medications and support day concluded with a keynote address from Barbara treatment programs. Bush, co-founder and CEO of Global Health Corps and daughter of President George W. Bush.

21 Global Network

Making NTDs a Priority

The Global Network cultivates support for NTD treatment from key governments and influencers.

Sabin works closely with stakeholders Through regular engagement with members of the at the Vatican, resulting in high- U.S. Congress, the Global Network and its END7 profile public statements on NTDs, campaign helped protect the USAID NTD budget including a 2015 speech in which against proposed cuts in 2015. Pope Francis included NTDs in a list of health issues requiring “urgent With leadership from Sabin’s U.K.-based sister political attention.” organization, Sabin Foundation Europe, advocacy by the Global Network contributed to the inclusion of NTDs in the £1 billion Ross Fund to fight malaria and WHAT'S NEXT NTDs, launched by the U.K. Government in 2015.

Sabin will serve as an official As two key international donors to global NTD planning partner for the November treatment programs, the Global Network pushed the 2016 International Conference of the U.S. and U.K. Governments to continue championing Pontifical Council for Health Care Workers at the Vatican on “Diseases of NTDs and encouraged other governments to join Solidarity” – both rare and neglected the global fight against NTDs, emphasizing the vital tropical diseases. importance of increasing resources in order to reach control and elimination goals.

22 Global Network

Building Global Awareness

The END7 campaign’s “How to Shock a Celebrity” video, featuring celebrities including Eddie Redmayne, Priyanka Chopra and Emily Blunt, reached 7 million views in 2015.

The Global Network advocated for an increased NTD budget on the Hill through testimonies, community letters, petitions and personal engagement with Members of Congress.

Photo: Sabin President Dr. Peter Hotez testifies before the U.S. House Subcommittee on Africa, Global Health, Global Human Rights and International Organizations on the threat of NTDs.

23 SABIN FOUNDATION EUROPE Promoting proven solutions to the world’s most pervasive health issues

24 Sabin Foundation Europe

Sabin Foundation Europe is Sabin’s sister organization based in the U.K., supporting the fight against vaccine- preventable and neglected tropical diseases through efforts across Europe.

Sabin Foundation Europe is a U.K.-registered charity In 2015, funds raised by the Foundation supported founded in 2011 to support vaccine research and programs to prevent and control lymphatic filariasis development, advocacy efforts and treatment programs and soil-transmitted helminths in Guyana and India, for vaccine-preventable and neglected tropical diseases in partnership with Sabin City Group and the END7 (NTDs). campaign. Sabin Foundation Europe was also named the official charity partner of the Thomson Reuters Sabin Foundation Europe collaborates with global health Capital Conference, a banking conference in the heart partners and coalitions to influence U.K. Government of London’s financial district, where the Foundation was policy on neglected health issues by engaging key able to introduce the issue of NTDs to a private-sector decision and policy makers. Sabin Foundation Europe audience and cultivate new champions. was elected in 2015 to chair the advocacy group for the U.K. Coalition against NTDs, a group of U.K.-based NTD researchers, implementers and advocates committed to WHAT'S NEXT raising awareness, influencing U.K. Government policy decisions and getting NTD control on the national, Sabin Foundation Europe will co-author an annual parliamentary NTD report regional and international development agendas. to be launched in 2016 and will forge partnerships in the U.K. to advance Sabin’s mission to end preventable diseases, targeting U.K. decision and policy makers.

25 Awards & Recognition

Awards & Recognition

Ambassador Michael W. Marine retired from his role as Sabin’s CEO in April 2016 after helming the organization for six years. We thank Ambassador Marine for his leadership, under which Sabin expanded its advocacy programs for vaccine- preventable diseases and NTDs, grew its vaccine development program through a partnership with Texas Children’s Hospital and Baylor College of Medicine, and launched END7, the world’s largest grassroots advocacy campaign supporting NTD control and elimination programs. Ambassador Marine will continue to serve Sabin’s mission on the Board of Trustees.

Sabin awarded its 2015 Albert B. Sabin Gold Medal Award to Dr. Roger I. Glass for his pioneering role in research and vaccine development for rotavirus. Rotavirus vaccines, including several that he has helped to develop, are now in use in more than 70 national immunization programs, and have had a major impact in reducing both deaths and diarrheal hospitalizations, improving the health of millions of children worldwide.

In 2015, Sabin’s President, Dr. Peter Hotez, served as U.S. Science Envoy for the White House and the U.S. Department of State. In this role, Dr. Hotez has worked with the international scientific community to stimulate increased scientific cooperation and foster economic prosperity. He is now laying the groundwork to establish centers of excellence for vaccine development in the Middle East and North Africa. Dr. Hotez will continue to serve in this role in 2016.

Sabin awarded the Albert B. Sabin Humanitarian Award in 2015 to Dr. Gary Michelson, a distinguished orthopedic spinal surgeon and inventor, in recognition of his extraordinary philanthropy and commitment toward the control and elimination of NTDs through high-level advocacy and vaccine research and development. As an innovator and a philanthropist, Dr. Michelson’s contributions to the field of science and technology have enabled millions of people to live healthier, more productive lives.

Carol Ruth Shepherd passed away in May 2016 at age 93. Carol Ruth and her late husband, HR Shepherd, founded Sabin in memory of Dr. Albert B. Sabin in 1993 with Dr. Sabin's widow, Mrs. Heloisa Sabin; Dr. Robert Chanock; and Dr. Philip Russell. The Shepherds forged a vision for Sabin’s future, inspiring a commitment to developing vaccines and advocating greater use of existing vaccines and medicine. At age 91, Carol Ruth and many family members proudly attended Sabin’s 20th Anniversary.

26 FINANCES Sabin has received the highest possible rating on Charity Navigator for nearly a decade.

27 Finances

Condensed Statement of Activities DECEMBER 31, 2015 AND 2014

2015 2014 REVENUE AND SUPPORT

Grants, contributions and other support received Sabin's Board of Trustees and Future portion of grants executive leadership are fully as of year-end committed to responsible Investment income and effective stewardship of donor funding. For the TOTAL eigth consecutive year, Sabin received Charity Navigator's 0 20M 40M 60M 80M highest rating possible EXPENSES for consistently executing our mission in a fiscally Program services responsible way. General, administrative and fundraising

TOTAL

0 20M 40M 60M 80M

EXCESS OF REVENUES, COMMITMENTS AND SUPPORT OVER EXPENSES

0 20M 40M 60M 80M

SPENDING EFFICIENCY RATIO: 89% 11% Program Services General, Administrative and Fundraising

28 Finances

Condensed Statement of Financial Position DECEMBER 31, 2015 AND 2014

The financial statements 2015 2014 presented have been ASSETS summarized from Sabin's audited financial statements. Sabin's full audit report, Cash, equivalents and other current assets completed by Rogers & Co, LLP, is available at Investments www.sabin.org. Other assets

TOTAL ASSETS

0 10M 20M 30M

LIABILITIES AND NET ASSETS ALLOCATION OF PROGRAM EXPENSES: Accounts payable and accrued expenses

Other liabilities 45% TOTAL LIABILITIES Vaccine Development

0 10M 20M 30M

Unrestricted net assets 41% Vaccine Advocacy Temporarily restricted net assets and Education

TOTAL NET ASSETS 0 10M 20M 30M 14% Global Network TOTAL LIABILITIES AND NET ASSETS 0 10M 20M 30M

29 Thank you to all of our partners . We are grateful for your support, which makes Sabin’s important work possible.

View all of Sabin's partners at sabin.org/thank-you-2015

Sabin Vaccine Institute 2000 Pennsylvania Avenue, NW Suite 7100 Washington, D.C. 20006 +1 202 842 5025 Credits PHOTO CREDITS: Olivier Asselin, Baylor College of Medicine, Mignonette Dooley, Visit sabin.org Anna Grove Photography, Yannis Guibinga, Donate at sabin.org/donate Esther Havens, Join the Lights, Timothy Mwaura, Víctor Norambuena, Naveen Pun DESIGN CREDIT: büro svenja : facebook.com/sabinvaccine DEVELOPMENT CREDIT: paperplane.co, : @sabinvaccine Echo & Co.